REPLIGEN CORP SEC 10-Q Report

Repligen Corp, a leading provider of advanced bioprocessing technologies and solutions, has released its Form 10-Q report for the first quarter of 2025. The report highlights significant financial growth and operational advancements, underscoring the company's robust performance in the bioprocessing industry.

Financial Highlights

Total Revenue: $169.2 million, increased by 10.4% compared to the same period in 2024, driven by strong performance in Chromatography and Analytics franchises.

Gross Profit: $90.8 million, representing a gross margin of 53.6%, an improvement from 50.1% in the prior year due to reduced materials consumed and consistent labor overhead costs.

Income from Operations: $6.6 million, reflecting an increase from $3.8 million in the previous year, attributed to higher sales and improved operational efficiency.

Net Income: $5.8 million, up from $3.3 million in the same period of 2024, with an effective tax rate of 26.6% compared to 10.8% in the prior year.

Diluted EPS: $0.10, compared to $0.06 in the first quarter of 2024, reflecting improved profitability and operational performance.

Business Highlights

Revenue Segments: Product revenue increased by 10.4% due to strong performance in the Chromatography and Analytics franchises, with a slight decline in Filtration revenue due to a large hardware sale in 2024 that did not recur in 2025.

Geographical Performance: North America accounted for 50% of total revenue, Europe for 35%, and APAC/Other regions for 15%, reflecting a stable distribution of sales across these regions.

New Product Launches: The acquisition of 908 Devices' PAT Portfolio added four new devices for bioprocessing process analytical technology applications, enhancing the company's product offerings.

New Production Launches: The acquisition of facilities in North Carolina and Braunschweig, Germany, as part of the 908 Devices PAT Portfolio acquisition, expanded the company's production capabilities.

Future Outlook: The company plans to continue investing in its bioprocessing business and R&D activities, with a focus on expanding its product lines and commercial capabilities. It also anticipates increased operating expenses due to these expansion efforts.

SEC Filing: REPLIGEN CORP [ RGEN ] - 10-Q - Apr. 29, 2025